Vertex Pharmaceuticals Incorporated (VRTX) Key Statistics & Financial Ratios

Vertex Pharmaceuticals Incorporated (VRTX) — Price $503.50 — Healthcare — Biotechnology — NASDAQ

Latest reported results:

Key statistics dashboard for Vertex Pharmaceuticals Incorporated (VRTX). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.

Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene.

Stock Data

Price$503.50
Market Cap$127.8B
Enterprise Value$123.62B
Beta0.37
ExchangeNASDAQ
CountryUS

Valuation Multiples

P/E Ratio29.07
Price / Book6.31
P/S10.12
EV/EBITDA22.71
EV/Sales9.79
EV/FCF32.57
P/FCF33.66
Earnings Yield3.45%
FCF Yield2.97%
Dividend Yield0.00%

Profitability

Gross Margin86.04%
EBIT Margin41.84%
EBITDA Margin43.13%
Operating Margin38.59%
Net Margin34.89%
Return on Equity23.31%
Return on Assets16.06%
Return on Invested Capital17.33%
Return on Capital Employed20.74%

Financial Health

Current Ratio3.19
Quick Ratio2.74
Cash Ratio1.56
Debt / Equity0.10
Debt / Assets7.21%
Net Debt / EBITDA-0.77
Interest Coverage738.18
Piotroski F-Score6
Altman Z-Score11.43

Per-Share Data

Revenue per share49.72
Book Value per share79.75
Cash per share30.93
FCF per share14.95
Tangible Book Value per share73.84
Dividend per share0.00

Analyst Consensus

Strong Buy0
Buy48
Hold7
Sell1
Strong Sell0
Total analysts56
Avg rating (1-5)0.84

Related companies: ARGX · BMY · CVS · GSK · HCA · MCK · MDT

Explore sector: Healthcare · Biotechnology

More sections of VRTX: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events

Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks